Navigation Links
Sequella Receives American Recovery and Reinvestment Funding Through the NIH
Date:10/5/2009

ROCKVILLE, Md., Oct. 5 /PRNewswire/ -- Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it received a $694,000 grant supplement as part of the American Recovery and Reinvestment Act (ARRA) of 2009. The ARRA funds, issued through the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institute of Health (NIH), will assist Sequella to complete the manufacture of its lead drug candidate, SQ109, and provide drug supplies to continue NIH grant-funded research on SQ109 mechanism of action.

SQ109 is a new small molecule drug that is currently under US IND for the treatment of tuberculosis and is completing its Phase I safety studies in humans. Single, oral doses of 5 to 300 mg SQ109 were safe and well-tolerated in normal, healthy adults in a phase 1A study. In collaboration with NIAID, the Phase 1B clinical study to evaluate safety and pharmacokinetics of SQ109 administered daily for 2 weeks began in May 2009.

"We are pleased to receive these ARRA funds," said Dr. Carol Nacy, CEO of Sequella. "The ARRA funds will contribute to SQ109 manufacture by subcontractors in four different states impacted by the current economic downturn. We are extremely appreciative of continued support from the NIH and of the Federal Government for providing ARRA funding opportunities."

This supplemental ARRA funding will be used to complete process development and finalize manufacture of SQ109 active pharmaceutical ingredient.

About Sequella

Sequella is a clinical stage biopharmaceutical company focused on commercializing improved treatments for infectious diseases of epidemic potential. The company leverages its global influence, R&D platforms, and infectious disease expertise to proactively address emerging health threats. Through focused execution, clear commercialization pathways, and strategic partnerships, Sequella intends to commercialize a broad product portfolio designed to treat global health threats with significant market opportunity.

About the NIH and NIAID

The National Institutes of Health (NIH) -- The Nation's Medical Research Agency -- includes 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

The National Institute of Allergy and Infectious Diseases (NIAID) conducts and supports research -- at NIH, throughout the United States, and worldwide -- to study the causes of infectious and immune-mediated diseases and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov. For comments from the NIAID regarding this grant, please contact 301-402-1663.

SOURCE Sequella, Inc.


'/>"/>
SOURCE Sequella, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Sequella Presents Data on Synergy Between Investigational New TB Drugs SQ109 and TMC207
2. Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program
3. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
4. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
7. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
8. CryoCor Receives FDA Approval for Right Atrial Flutter
9. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
10. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
11. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)...   Click here for supplemental information regarding ... the nation,s largest independent specialty pharmacy, announced today ... acquire Valley Campus Pharmacy, Inc., doing business as ... pharmacy that provides individualized patient care, based in ... 2015, TNH generated approximately $400 million in revenue. ...
(Date:4/28/2016)... Calif. , April 28, 2016  Marking ... widely accessible breast and ovarian cancer risk test, ... panel analyzing 30 genes that highly impact the ... women. Available today, the Color Test analyzes hereditary ... prostate, stomach, and uterine cancers. The Color Test ...
(Date:4/28/2016)... , April 28, 2016 ... insights on healthcare, announced today that it has been ... Cool Vendor in Life Sciences, 2016, ... 2016.  The report focuses on life-science- oriented analytics, algorithms ... from patients and doctors, confirm medication ingestion, and analyze ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... The American ... productivity, stability, even security. Most importantly, employees are the single most important asset ... American workers so unhappy? , Just under half of American workers are emotionally ...
(Date:4/29/2016)... , ... April 29, 2016 , ... Conditions were ideal ... Cove Island Park on Sunday, with sunny skies, a light breeze and temperatures in ... $33,000. , The 5k Run and Walk and 1-mile walk were held ...
(Date:4/29/2016)... ... ... Spine Team Texas, a comprehensive spine physician group specializing in the treatment ... been invited to be a featured speaker at the Texas Society of the American ... 2016. , Dr. R. Scott McPherson, a physical medicine and rehabilitation specialist, will ...
(Date:4/29/2016)... NY (PRWEB) , ... April 29, 2016 , ... ... and engineer of patented products, announces the Gyrociser, an exercise invention which aids ... worth $2 billion," says Scott Cooper, CEO and Creative Director of World Patent ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Dr. Robert ... dental treatments to improve smiles. Cosmetic dentistry is a fast-growing field as more patients ... offer allows patients to learn more about the options currently available to them and ...
Breaking Medicine News(10 mins):